InsidersTradesSigma
Track the Hims & Hers Health, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Hims & Hers Health, Inc. has recorded 625 reports. Market capitalisation: €6.7bn. The latest transaction was filed on 3 September 2026 (Cession). Among the most active insiders: Okupe Oluyemi. Every trade is openly available.
625
Insider Decl.
n/a
Thresholds
€4m
8 ops.
Buy Volume
€82m
177 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Hims & Hers Health, Inc. Hold (neutral), based on 13 analysts. Average price target: US$31.23.
35Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,504 of 29,063 companies
35.4
score / 100
Value30
Quality41
FCF yld0.9%
Earn yld1.9%
EV/EBITDA49.0x
ROE-32%
Gross mgn74%
Net mgn5.5%
Debt/EBITDA7.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations625 total
3,458 shares@ US$28.330.0015% mcap0.8% of flowClass A Common StockSEC:0001837817-26-000013:0
463,289 shares0Class A Common StockSEC:0001773751-26-000217:0
977,566 shares0Class A Common StockSEC:0001773751-26-000217:1
16,773 shares@ US$27.850.0074% mcap28.4% of flowClass A Common StockSEC:0001884671-26-000004:0
25,111 shares@ US$27.550.011% mcap5.2% of flowClass A Common StockSEC:0001837817-26-000011:0
4,938 shares@ US$5.010.0004% mcap0.1% of flowClass A Common StockSEC:0001907056-26-000022:0
4,938 shares@ US$29.99420.0023% mcap0.7% of flowClass A Common StockSEC:0001907056-26-000022:1
25,111 shares@ US$27.550.011% mcap5.5% of flowClass ASEC144:0001959173-26-006194
16,773 shares@ US$27.850.0073% mcap39.6% of flowClass ASEC144:0001959173-26-006133
13,685 sharesClass A Common StockSEC:0001773751-26-000206:0
86,265 sharesClass A Common StockSEC:0001773751-26-000211:0
154,993 sharesClass A Common StockSEC:0001773751-26-000212:0
6,623 sharesClass A Common StockSEC:0001773751-26-000214:0
32,920 sharesClass A Common StockSEC:0001773751-26-000209:0
6,490 shares@ US$28.150.0028% mcap5.9% of flowClass A Common StockSEC:0001773751-26-000206:1
42,261 sharesClass A Common StockSEC:0001773751-26-000215:0
21,500 shares@ US$28.150.0092% mcap5.1% of flowClass A Common StockSEC:0001773751-26-000215:1
260 sharesClass A Common StockSEC:0001773751-26-000213:0
25,927 sharesClass A Common StockSEC:0001773751-26-000213:1
10,201 shares@ US$28.150.0044% mcap4.5% of flowClass A Common StockSEC:0001773751-26-000213:2
47,702 shares@ US$28.150.021% mcap9.4% of flowClass A Common StockSEC:0001773751-26-000211:1
78,859 shares@ US$28.150.034% mcap3.1% of flowClass A Common StockSEC:0001773751-26-000212:1
188,285 sharesClass A Common StockSEC:0001773751-26-000207:0
95,798 shares@ US$28.150.041% mcap74.0% of flowClass A Common StockSEC:0001773751-26-000207:1
545 sharesClass A Common StockSEC:0001773751-26-000205:0
25 of 625 declarations
关于 Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (NYSE: HIMS) 是一家在美国上市的消费者健康和远程医疗平台，总部位于美国加利福尼亚州旧金山。该公司由 Andrew Dudum、Hilary Coles、Jack Abraham 和 Joe Spector 于 2017 年在风险投资工作室 Atomic 创立，其核心业务模式是直接面向消费者，旨在让医疗保健更便捷、更易获得、更个性化。Hims & Hers 从最初的数字原生品牌发展成为一个多专科护理平台，将客户与持牌医疗专业人员以及更广泛的健康和保健产品及服务连接起来。([investors.hims.com](https://investors.hims.com/news/news-details/2021/Hims--Hers-Appoints-Two-New-Board-Members/default.aspx?utm_source=openai)) 公司的核心业务涵盖多个消费者医疗保健类别，包括性健康、皮肤病学、心理健康、脱发、初级保健、心脏健康、体重管理以及其他与健康相关的产品。其模式结合了远程医疗咨询、临床医生主导的护理路径、适时的处方配药以及通过数字化客户体验提供的品牌产品。这种综合方法是公司竞争定位的核心：Hims & Hers 不仅仅是一个远程医疗市场，而是一个品牌主导的护理平台，旨在提高参与度、依从性和客户保留率。管理层一直强调个性化、简单性和可负担性是其在竞争激烈且不断发展的数字健康市场中的关键差异化因素。([investors.hims.com](https://investors.hims.com/news/news-details/2021/Hims--Hers-Appoints-Two-New-Board-Members/default.aspx?utm_source=openai)) 从地理上看，该公司首先在美国建立了规模，并报告其服务覆盖所有 50 个州和华盛顿特区。最近，它已不再局限于纯粹的国内业务，正在推行国际增长战略。2026 年，Hims & Hers 宣布达成协议收购 Eucalyptus，此举旨在加速其成为全球领先消费者健康平台的雄心。此举预示着美国市场之外更广阔的长期机遇，同时也增加了执行和监管的复杂性。([investors.hims.com](https://investors.hims.com/news/news-details/2021/Hims--Hers-Appoints-Two-New-Board-Members/default.aspx?utm_source=openai)) 近期发展强化了公司的增长叙事。2026 年 5 月，Hims & Hers 报告 2026 年第一季度收入约为 $608 million，订阅用户增长至近 2.6 million，并上调了 2026 年全年业绩指引。公司还继续扩大其产品组合，包括女性健康、体重管理解决方案、多癌早期检测以及基于合作伙伴的健康福利。因此，对于投资者而言，股权案例基于快速的营收增长、产品扩张、品牌实力和可扩展的数字分销模式，同时伴随着远程医疗行业常见的与监管、临床审查和竞争强度相关的风险。([investors.hims.com](https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-First-Quarter-2026-Financial-Results/default.aspx?utm_source=openai))
